|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/07/23 Cell MedX Corp. 10-K 5/31/22 90:3.6M Empire Stock Transf… Inc |
Document/Exhibit Description Pages Size
1: 10-K Cell Medx Corp. - Form 10-K SEC Filing HTML 801K
2: EX-10.50 Loan Agreement and Note Payable Dated April 28, HTML 30K
2022, Among Cell Medx (Canada) Corp. and Richard
Jeffs
3: EX-10.51 Loan Agreement and Note Payable Dated May 31, HTML 30K
2022, Among Cell Medx (Canada) Corp. and Richard
Jeffs
4: EX-10.52 Loan Agreement and Note Payable Dated June 27, HTML 30K
2022, Among Cell Medx (Canada) Corp. and Richard
Jeffs
5: EX-10.53 Loan Agreement and Note Payable Dated July 28, HTML 30K
2022, Among Cell Medx (Canada) Corp. and Richard
Jeffs
6: EX-10.59 Loan Agreement Dated September 2, 2022, Among Cell HTML 27K
Medx (Canada) Corp. and Richard Jeffs
7: EX-10.60 Loan Agreement Dated September 6, 2022, Among Cell HTML 28K
Medx (Canada) Corp. and Richard Jeffs
8: EX-10.61 Loan Agreement Dated November 3, 2022, Among Cell HTML 28K
Medx (Canada) Corp. and Richard Jeffs
9: EX-10.62 Loan Agreement Dated November 28, 2022, Among Cell HTML 31K
Medx (Canada) Corp. and Richard Jeffs
10: EX-10.63 Loan Agreement Dated December 30, 2022, Among Cell HTML 28K
Medx (Canada) Corp. and Richard Jeffs
11: EX-10.64 Loan Agreement Dated January 24, 2023, Among Cell HTML 32K
Medx Corp. and David Jeffs
12: EX-10.65 Loan Agreement Dated January 24, 2023, Among Cell HTML 32K
Medx Corp. and Amir Vahabzadeh
13: EX-10.66 Loan Agreement Dated January 30, 2022, Among Cell HTML 27K
Medx (Canada) Corp. and Richard Jeffs
14: EX-21.1 List of Significant Subsidiaries HTML 26K
15: EX-31.1 Certification -- §302 - SOA'02 HTML 29K
16: EX-31.2 Certification -- §302 - SOA'02 HTML 29K
17: EX-32.1 Certification -- §906 - SOA'02 HTML 26K
18: EX-32.2 Certification -- §906 - SOA'02 HTML 26K
24: R1 Document and Entity Information HTML 86K
25: R2 Consolidated Balance Sheets HTML 106K
26: R3 Consolidated Balance Sheets - Parenthetical HTML 33K
27: R4 Consolidated Statements of Operations HTML 99K
28: R5 Consolidated Statement of Stockholders' Deficit HTML 86K
29: R6 Consolidated Statements of Cash Flows HTML 97K
30: R7 Organization and Nature of Operations HTML 31K
31: R8 Summary of Significant Accounting Policies HTML 48K
32: R9 Related Party Transactions Disclosure HTML 48K
33: R10 Notes and Advances Payable Disclosure HTML 47K
34: R11 Other Current Assets Disclosure HTML 28K
35: R12 Equipment Disclosure HTML 34K
36: R13 Revenue Disclosure HTML 34K
37: R14 Notes and Advances Payable Disclosure, Current HTML 28K
38: R15 Stockholders' Deficit Disclosure HTML 59K
39: R16 Income Taxes Disclosure HTML 47K
40: R17 Subsequent Events Disclosure HTML 30K
41: R18 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis HTML 28K
of Presentation (Policies)
42: R19 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 29K
Principles of Consolidation, Policy (Policies)
43: R20 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 31K
Accounting Estimates, Policy (Policies)
44: R21 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 30K
Foreign Currency Translations and Transactions,
Policy (Policies)
45: R22 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 30K
Revenue Recognition, Policy (Policies)
46: R23 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 30K
Inventory Valuation, Policy (Policies)
47: R24 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 29K
Research and Development Costs, Policy (Policies)
48: R25 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Income HTML 31K
Taxes, Policy (Policies)
49: R26 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 34K
Earnings Per Share, Policy (Policies)
50: R27 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 30K
Long-lived Assets, Policy (Policies)
51: R28 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 29K
Equipment, Policy (Policies)
52: R29 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair HTML 31K
Value Measurements, Policy (Policies)
53: R30 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock HTML 32K
Options and Other Stock-based Compensation, Policy
(Policies)
54: R31 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent HTML 28K
Accounting Pronouncements (Policies)
55: R32 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 33K
Earnings Per Share, Policy: Schedule of
Antidilutive Securities Excluded from Computation
of Earnings Per Share (Tables)
56: R33 Related Party Transactions Disclosure: Schedule of HTML 36K
Amounts Due to Related Parties (Tables)
57: R34 Related Party Transactions Disclosure: Schedule of HTML 36K
Transactions with Related Parties (Tables)
58: R35 Notes and Advances Payable Disclosure: Schedule of HTML 39K
Loans and Advances Outstanding to Related Parties
(Tables)
59: R36 Equipment Disclosure: Change in book value of the HTML 33K
equipment (Tables)
60: R37 Revenue Disclosure: Schedule of Revenue and HTML 34K
Associated Costs (Tables)
61: R38 Stockholders' Deficit Disclosure: Schedule of HTML 36K
Stock Option Activity (Tables)
62: R39 Stockholders' Deficit Disclosure: Schedule of HTML 31K
Stock Options Outstanding (Tables)
63: R40 Stockholders' Deficit Disclosure: Schedule of HTML 36K
Warrant Activity (Tables)
64: R41 Stockholders' Deficit Disclosure: Schedule of HTML 32K
Warrant Details (Tables)
65: R42 Income Taxes Disclosure: Schedule of Effective HTML 37K
Income Tax Rate Reconciliation (Tables)
66: R43 Income Taxes Disclosure: Schedule of Deferred Tax HTML 34K
Assets and Liabilities (Tables)
67: R44 Organization and Nature of Operations (Details) HTML 30K
68: R45 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 31K
Earnings Per Share, Policy: Schedule of
Antidilutive Securities Excluded from Computation
of Earnings Per Share (Details)
69: R46 Related Party Transactions Disclosure: Schedule of HTML 39K
Amounts Due to Related Parties (Details)
70: R47 Related Party Transactions Disclosure: Schedule of HTML 40K
Transactions with Related Parties (Details)
71: R48 Notes and Advances Payable Disclosure: Schedule of HTML 39K
Loans and Advances Outstanding to Related Parties
(Details)
72: R49 Notes and Advances Payable Disclosure (Details) HTML 65K
73: R50 Other Current Assets Disclosure (Details) HTML 30K
74: R51 Equipment Disclosure: Change in book value of the HTML 36K
equipment (Details)
75: R52 Revenue Disclosure: Schedule of Revenue and HTML 49K
Associated Costs (Details)
76: R53 Notes and Advances Payable Disclosure, Current HTML 35K
(Details)
77: R54 Stockholders' Deficit Disclosure (Details) HTML 78K
78: R55 Stockholders' Deficit Disclosure: Schedule of HTML 41K
Stock Option Activity (Details)
79: R56 Stockholders' Deficit Disclosure: Schedule of HTML 31K
Stock Options Outstanding (Details)
80: R57 Stockholders' Deficit Disclosure: Schedule of HTML 34K
Warrant Activity (Details)
81: R58 Stockholders' Deficit Disclosure: Schedule of HTML 33K
Warrant Details (Details)
82: R59 Income Taxes Disclosure: Schedule of Effective HTML 54K
Income Tax Rate Reconciliation (Details)
83: R60 Income Taxes Disclosure: Schedule of Deferred Tax HTML 37K
Assets and Liabilities (Details)
84: R61 Income Taxes Disclosure (Details) HTML 30K
85: R62 Subsequent Events Disclosure (Details) HTML 34K
88: XML IDEA XML File -- Filing Summary XML 153K
86: XML XBRL Instance -- cmxc-20220531_htm XML 666K
87: EXCEL IDEA Workbook of Financial Reports XLSX 98K
19: EX-101.CAL XBRL Calculations -- cmxc-20220531_cal XML 69K
20: EX-101.DEF XBRL Definitions -- cmxc-20220531_def XML 298K
21: EX-101.LAB XBRL Labels -- cmxc-20220531_lab XML 526K
22: EX-101.PRE XBRL Presentations -- cmxc-20220531_pre XML 484K
23: EX-101.SCH XBRL Schema -- cmxc-20220531 XSD 145K
89: JSON XBRL Instance as JSON Data -- MetaLinks 258± 387K
90: ZIP XBRL Zipped Folder -- 0001393905-23-000167-xbrl Zip 222K
| Loan Agreement dated January 24, 2023, among Cell MedX Corp. and David Jeffs |
LOAN AGREEMENT
THIS LOAN AGREEMENT (the “Agreement”) dated this 24th day of January, 2023
BETWEEN:
David M. Jeffs of 2615 15th Avenue West, Vancouver, BC V6K 2Z6, Canada
(the “Lender”)
OF THE FIRST PART
AND
Cell MedX Corp. of 123 W. Nye Lane, Suite 446, Carson City, NV 89706, USA
(the “Borrower”)
OF THE SECOND PART
IN CONSIDERATION OF the Lender loaning certain monies (the “Loan”) to the Borrower, and the Borrower repaying the Loan to the Lender, both parties agree to keep, perform and fulfill the promises and conditions set out in this Agreement:
Loan Amount & Interest
The Lender promises to lend thirty thousand ($30,000.00) US (the “Principal Amount”), to the Borrower and the Borrower promises to repay this Principal Amount to the Lender, at such address as may be provided in writing, with interest calculated and compounded monthly on the unpaid Principal Amount at the rate of 10.0% per annum.
Payment
This Loan will be repaid in full three (3) months from the execution of this Agreement.
At any time while not in default under this Agreement, the Borrower may pay the outstanding balance then owing under this Agreement to the Lender without further bonus or penalty.
Default
Notwithstanding anything to the contrary in this Agreement, if the Borrower defaults in the performance of any obligation under this Agreement, then the Lender may declare the Principal Amount owing and interest due under this Agreement at that time to be immediately due and payable.
Governing Law
This Agreement will be construed in accordance with and governed by the laws of the Province of British Columbia.
Costs
All costs, expenses and expenditures including, without limitation, the complete legal costs incurred by enforcing this Agreement as a result of any default by the Borrower, will be added to the Principal Amount then outstanding and any accrued interest thereon, and will immediately be paid by the Borrower.
Binding Effect
This Agreement will pass to the benefit of and be binding upon the respective heirs, executors, administrators, successors and permitted assigns of the Lender. The Borrower waives presentment for payment, notice of non-payment, protest, and notice of protest.
Amendments
This Agreement may only be amended or modified by a written instrument executed by both the Borrower and the Lender.
Severability
The clauses and paragraphs contained in this Agreement are intended to be read and construed independently of each other. If any term, covenant, condition or provision of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, it is the parties' intent that such provision be reduced in scope by the court only to the extent deemed necessary by that court to render the provision reasonable and enforceable and the remainder of the provisions of this Agreement will in no way be affected, impaired or invalidated as a result.
General Provisions
Headings are inserted for the convenience of the parties only and are not to be considered when interpreting this Agreement. Words in the singular mean and include the plural and vice versa. Words in the masculine mean and include the feminine and vice versa.
Entire Agreement
This Agreement constitutes the entire agreement between the parties and there are no further items or provisions, either oral or otherwise.
IN WITNESS WHEREOF, the parties have duly affixed their signatures under hand and seal on this 24th day of January, 2023.
| Cell MedX Corp. | |
/s/ David M. Jeffs |
| |
|
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/15/24 Cell MedX Corp. 10-Q 2/29/24 53:2.7M Empire Stock Transf… Inc 1/16/24 Cell MedX Corp. 10-Q 11/30/23 46:2.3M Empire Stock Transf… Inc 10/16/23 Cell MedX Corp. 10-Q 8/31/23 42:1.9M Empire Stock Transf… Inc 9/01/23 Cell MedX Corp. 10-K 5/31/23 73:3.2M Empire Stock Transf… Inc 6/29/23 Cell MedX Corp. 10-Q 2/28/23 53:2.5M Empire Stock Transf… Inc 5/19/23 Cell MedX Corp. 10-Q 11/30/22 53:2.4M Empire Stock Transf… Inc 4/19/23 Cell MedX Corp. 10-Q 8/31/22 51:2.2M Empire Stock Transf… Inc |